Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.5200
-0.0216 (-3.99%)
At close: Nov 3, 2025, 4:00 PM EST
0.5201
+0.0001 (0.02%)
After-hours: Nov 3, 2025, 4:42 PM EST
Silo Pharma Employees
Silo Pharma had 3 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$24,034
Profits / Employee
-$1,631,721
Market Cap
6.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 1 | 50.00% |
| Dec 31, 2021 | 2 | 1 | 100.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SILO News
- 5 days ago - Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain - GlobeNewsWire
- 11 days ago - Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program - GlobeNewsWire
- 26 days ago - Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth - GlobeNewsWire
- 4 weeks ago - Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci) - GlobeNewsWire
- 4 weeks ago - Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 4 weeks ago - Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 6 weeks ago - Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy - GlobeNewsWire
- 7 weeks ago - Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug - GlobeNewsWire